Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | PKM | P14618 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1619487 | 0.89 | CLK1 (0.53) | KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL1621410 | 0.89 | MAPT (0.54) | KMT2AMEN1RAB9AMAPTALDH1A1 | |
| SCHEMBL1621153 | 0.83 | ALDH1A1 (0.55) | KMT2AMEN1RAB9AMAPTKDM4E | |
| SCHEMBL1619602 | 0.83 | ABL1 (0.58) | KMT2AMEN1RAB9AMAPTALDH1A1 | |
| SCHEMBL1621442 | 0.82 | KDM4A (0.58) | KMT2AMEN1RAB9AMAPTKDM4E | |
| SCHEMBL1621098 | 0.81 | HTT (0.51) | KMT2AMEN1RAB9AMAPTKDM4E | |
| SCHEMBL3658990 | 0.80 | LMNA (0.53) | KMT2AMEN1RAB9AMAPTKDM4E | |
| SCHEMBL1464917 | 0.80 | MEN1 (0.64) | KMT2AMEN1RAB9AMAPTKDM4E | |
| SCHEMBL1464561 | 0.77 | SMN1; SMN2 (0.53) | KMT2AMEN1RAB9AMAPTKDM4E | |
| SCHEMBL1621015 | 0.76 | ATAD2 (0.49) | KMT2AMEN1RAB9AMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8829034-B2 | Compounds which modulate the CB2 receptor | Boehringer Ingerlheim International GmbH (DE) | 2014-09-09 | — | — | US | claimed |
| EP-2074084-B1 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INT (DE) | 2013-08-28 | — | — | EP | claimed |
| US-20110130431-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-02 | — | — | US | claimed |
| US-20080081822-A1 | N-(5-tert-Butyl-isoxazol-3-yl)-2-cyclohexanesulfonyl-2-methyl-propionamide; cannabinoid receptor agonist, antagonist; analgesic, antiinflammatory and antitumor agent; neuropatic pain | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-04-03 | — | — | US | claimed |
| US-8829034-B2 | Compounds which modulate the CB2 receptor | Boehringer Ingerlheim International GmbH (DE) | 2014-09-09 | — | — | US | disclosed |
| EP-2074084-B1 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INT (DE) | 2013-08-28 | — | — | EP | disclosed |
| US-20110130431-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-02 | — | — | US | disclosed |
| US-7928123-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-19 | — | — | US | disclosed |
| US-20080081822-A1 | N-(5-tert-Butyl-isoxazol-3-yl)-2-cyclohexanesulfonyl-2-methyl-propionamide; cannabinoid receptor agonist, antagonist; analgesic, antiinflammatory and antitumor agent; neuropatic pain | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081822-A1 | N-(5-tert-Butyl-isoxazol-3-yl)-2-cyclohexanesulfonyl-2-methyl-propionamide; cannabinoid receptor agonist, antagonist; analgesic, antiinflammatory and antitumor agent; neuropatic pain | CNR2, CNR1, OPRL1 | KMT2A 1326/4885MEN1 4477/4885RAB9A 3649/4885 |
| US-20110130431-A1 | Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | KMT2A 3720/4885MEN1 4811/4885RAB9A 2288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.